Risk Factors for Isoniazid Hepatotoxicity in Children With Latent TB and TB: Difference From Adults

To the Editor:
Isoniazid (INH) is still the mainstay of the treatment of both active and latent TB. The main adverse effect of this worldwideused drug was hepatotoxicity, which had a wide spectrum, changing from mild transient elevations 1 in aminotransferases to severe hepatitis leading to liver transplantation. 2 The incidence of INH hepatotoxicity was reported to range from 0.1 at the low end to from 4% to 8% at the high end in different studies. The studies concerning childhood TB and INH hepatotoxicity in children were limited and composed of reports in which children and adults were evaluated together.
We aimed to determine the overall incidence of severe and mild INH hepatotoxicity and the effect of age in children. Patients during the period from 2002 to January 2009 with the diagnosis of TB or latent infection were included. World Health Organization Toxicity Classifi cation Standards were used for the evaluation of INH hepatotoxicity. Overall hepatotoxicity was observed in 12 patients (1.7%) of 695 patients, whereas 4 patients (0.57%) had moderate-to-severe hepatotoxicity ( Table 1 ). There were no statistical differences in the incidence of overall hepatotoxicity, grade I to II hepatotoxicity, and grade III to IV hepatotoxicity when the patients with TB and latent TB were compared ( P . 0.05). There was no statistical difference in the incidence of overall toxicity in age groups (aged , 5 years, 5-10 years, Ն 10 years) ( P . 0.05). Older age was a risk factor for hepatotoxicity in adults, 2 , 4 whereas smaller children were reported to be under risk 5 in childhood. However, our study did not demonstrate any age-specifi c difference for hepatotoxicity.
Table 1 -Incidence of Hepatotoxicity
In conclusion, severe hepatotoxicity in children was found to be lower than reported before, and age did not affect the incidence of INH hepatotoxicity, as it did in adults. Nevertheless, the potential of anti-TB drugs for hepatotoxicity and liver failure in children should be kept in mind. 
Use of Antisialogogues in Bronchoscopy
To the Editor:
In their recent article in CHEST (August 2009), Malik et al 1 suggest that use of anticholinergic premedication may reduce airway secretions during bronchoscopy but not cough, patient discomfort, oxygen desaturation, or procedure time. However, a review of their data does not truly support a clinically important difference, even for secretion reduction. We found the design of their study to be strikingly similar to our initial randomized, double-blind, placebo-controlled study of atropine and glycopyrrolate published in 2000 within this same journal (July 2000) . 2 The only real difference between our study and the Malik study published 9 years later was the total number of patients enrolled; in fact, the fi ndings are nearly identical. We designed our initial study to have 80% statistical power ( b ) of detecting a 12% difference between the mean values recorded on a visual analog scale for the primary end point of control of respiratory tract secretions. This difference was estimated to be the minimum required to make the use of these medications clinically important. To achieve this level of power, approximately 210 patients were calculated to have been required for the study, 70 in each group. Although Malik and colleagues enrolled 1,000 consecutive patients who were eligible, they unfortunately did not report the level of statistical power to which they designed their study. If they did, one would likely see that the minimal difference in visual analog scale scores reported was barely statistically signifi cant, and hardly clinically generalizable.
In summary, there is now a multitude of published data demonstrating that administration of antisecretory drugs prior to bronchoscopy does not reduce procedure times, does not result in clinically signifi cant differences in cough or secretion control, and in some cases may actually result in clinical harm. Its routine use should be abandoned.
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